17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed malignant solid tumor OR lymphoma Metastatic or unresectable disease Standard curative or palliative measures are not available OR are associated with minimal survival benefit No known brain metastases Treated brain metastases allowed provided they have been stable ≥ 6 months without steroids or anti-seizure medications PATIENT CHARACTERISTICS: Age 18 and over Performance status ECOG 0-2 OR Karnofsky 60-100% Life expectancy More than 3 months Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hemoglobin > 8 g/dL Hepatic AST and ALT ≤ 2 times upper limit of normal Bilirubin ≤ 1.5 times normal PT and PTT ≤ 1.5 times normal (unless due to the presence of lupus anticoagulant or stable anticoagulation) Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No orthostatic hypotension > grade 2 (requiring more than brief fluid replacement or other therapy OR with physiological consequences) No New York Heart Association class III or IV heart failure LVEF ≥ 40% by MUGA QTc ≤ 450 msec (470 msec for women) No congenital long QT syndrome No myocardial infarction within the past year No active ischemic heart disease within the past year No history of uncontrolled dysrhythmias No history of serious ventricular arrhythmia (ventricular fibrillation or ventricular tachycardia > 3 premature ventricular contractions in a row) Not requiring antiarrhythmic drugs No poorly controlled angina No left bundle branch block Pulmonary No uncontrolled symptomatic pulmonary disease, including any of the following: Dyspnea off or on exertion Paroxysmal nocturnal dyspnea Severe chronic obstructive/restrictive pulmonary disease requiring daily chronic medications and oxygen Must not meet the Medicare criteria for home oxygen No sufficiently compromised pulmonary status as measured by baseline pulmonary function tests and DLCO Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 2 months after study participation No known HIV positivity No hyponatremia indicated by sodium < 130 mmol/L No known immunodeficiency syndromes No history of allergic reaction attributed to compounds of similar chemical or biological composition to 17-dimethylaminoethylamino-17-demethoxygeldanamycin (geldanamycin or 17-AAG) No concurrent uncontrolled illness No active or ongoing uncontrolled infection No psychiatric illness or social situation that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy More than 4 weeks since prior biologic therapy and recovered No concurrent prophylactic growth factors Chemotherapy More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin, 8 weeks for UCN-01) and recovered Endocrine therapy See Disease Characteristics Concurrent hormonal therapy for prostate cancer allowed provided patient has metastatic disease that has progressed despite prior hormonal therapy Radiotherapy More than 4 weeks since prior radiotherapy and recovered No prior radiotherapy that included the heart in the field (e.g., mantle radiotherapy) Surgery At least 4 weeks since prior major surgery Other At least 2 weeks since prior participation in a phase 0 study Concurrent bisphosphonates for any cancer allowed Concurrent preventative doses of aspirin or non-steroidal anti-inflammatory drugs allowed No concurrent drugs that may prolong QTc interval No concurrent full anticoagulation on a regular basis No concurrent prophylactic antiemetics No other concurrent investigational agents or therapies No other concurrent anticancer agents or therapies